CA2159355C - Methode et composition pour le traitement de l'osteoporose - Google Patents

Methode et composition pour le traitement de l'osteoporose Download PDF

Info

Publication number: CA2159355C
Authority: CA; Canada
Prior art keywords: human; potassium salt; thiazide diuretic; alkalinizing; thiazide
Prior art date: 1993-04-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA002159355A

Other languages

English (en)

Other versions

CA2159355A1 (fr

Inventor

R. Curtis Morris Jr.

Anthony Sebastian

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of California San Diego UCSD

Original Assignee

University of California San Diego UCSD

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-04-02

Filing date

1994-03-29

Publication date

2006-12-12

1994-03-29 Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD

1994-03-29 Priority claimed from PCT/US1994/003403 external-priority patent/WO1994022312A1/fr

1994-10-13 Publication of CA2159355A1 publication Critical patent/CA2159355A1/fr

2006-12-12 Application granted granted Critical

2006-12-12 Publication of CA2159355C publication Critical patent/CA2159355C/fr

2014-03-29 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims description 21
239000000203 mixture Substances 0.000 title claims description 19
238000011282 treatment Methods 0.000 title claims description 19
208000001132 Osteoporosis Diseases 0.000 title abstract description 24
239000003451 thiazide diuretic agent Substances 0.000 claims abstract description 68
229940121792 Thiazide diuretic Drugs 0.000 claims abstract description 40
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims abstract description 37
239000004480 active ingredient Substances 0.000 claims abstract description 17
239000011736 potassium bicarbonate Substances 0.000 claims abstract description 17
235000015497 potassium bicarbonate Nutrition 0.000 claims abstract description 17
229910000028 potassium bicarbonate Inorganic materials 0.000 claims abstract description 17
TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims abstract description 17
159000000001 potassium salts Chemical class 0.000 claims abstract description 14
210000002700 urine Anatomy 0.000 claims abstract description 12
150000001735 carboxylic acids Chemical class 0.000 claims abstract description 8
239000012530 fluid Substances 0.000 claims abstract description 8
238000001727 in vivo Methods 0.000 claims abstract 6
230000029142 excretion Effects 0.000 claims description 25
230000002485 urinary effect Effects 0.000 claims description 21
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims description 18
239000002552 dosage form Substances 0.000 claims description 14
239000003814 drug Substances 0.000 claims description 13
229960002003 hydrochlorothiazide Drugs 0.000 claims description 12
102000008186 Collagen Human genes 0.000 claims description 11
108010035532 Collagen Proteins 0.000 claims description 11
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 11
102000004067 Osteocalcin Human genes 0.000 claims description 11
108090000573 Osteocalcin Proteins 0.000 claims description 11
229920001436 collagen Polymers 0.000 claims description 11
239000002934 diuretic Substances 0.000 claims description 11
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims description 11
229960002591 hydroxyproline Drugs 0.000 claims description 11
230000001009 osteoporotic effect Effects 0.000 claims description 11
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims description 11
JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 claims description 10
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 10
239000011575 calcium Substances 0.000 claims description 10
229910052791 calcium Inorganic materials 0.000 claims description 10
229940079593 drug Drugs 0.000 claims description 10
241000282412 Homo Species 0.000 claims description 9
201000010099 disease Diseases 0.000 claims description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
239000011574 phosphorus Substances 0.000 claims description 8
229910052698 phosphorus Inorganic materials 0.000 claims description 8
210000002966 serum Anatomy 0.000 claims description 8
229940097420 Diuretic Drugs 0.000 claims description 6
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 6
229960002155 chlorothiazide Drugs 0.000 claims description 6
230000001882 diuretic effect Effects 0.000 claims description 6
JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 claims description 3
229960001523 chlortalidone Drugs 0.000 claims description 3
238000002360 preparation method Methods 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims 4
JIVPVXMEBJLZRO-UHFFFAOYSA-N chlorthalidone Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-UHFFFAOYSA-N 0.000 claims 3
-1 hydroxyl ions Chemical class 0.000 abstract description 6
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 abstract description 2
229940000425 combination drug Drugs 0.000 description 12
239000004615 ingredient Substances 0.000 description 12
230000000694 effects Effects 0.000 description 10
239000003826 tablet Substances 0.000 description 10
150000003839 salts Chemical class 0.000 description 9
230000007423 decrease Effects 0.000 description 6
230000011164 ossification Effects 0.000 description 6
210000000988 bone and bone Anatomy 0.000 description 5
229940030606 diuretics Drugs 0.000 description 5
239000006187 pill Substances 0.000 description 5
239000007787 solid Substances 0.000 description 5
239000002775 capsule Substances 0.000 description 4
235000018823 dietary intake Nutrition 0.000 description 4
230000036541 health Effects 0.000 description 4
230000002302 hypocalciuric effect Effects 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
208000006386 Bone Resorption Diseases 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
206010020772 Hypertension Diseases 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000024279 bone resorption Effects 0.000 description 3
210000003608 fece Anatomy 0.000 description 3
239000008187 granular material Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000003550 marker Substances 0.000 description 3
231100000252 nontoxic Toxicity 0.000 description 3
230000003000 nontoxic effect Effects 0.000 description 3
230000036515 potency Effects 0.000 description 3
239000000843 powder Substances 0.000 description 3
206010065687 Bone loss Diseases 0.000 description 2
ZAHDXEIQWWLQQL-IHRRRGAJSA-N Deoxypyridinoline Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(O)=C(C[C@H](N)C([O-])=O)C(CC[C@H](N)C(O)=O)=C1 ZAHDXEIQWWLQQL-IHRRRGAJSA-N 0.000 description 2
206010017076 Fracture Diseases 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
LCYXYLLJXMAEMT-SAXRGWBVSA-N Pyridinoline Chemical compound OC(=O)[C@@H](N)CCC1=C[N+](C[C@H](O)CC[C@H](N)C([O-])=O)=CC(O)=C1C[C@H](N)C(O)=O LCYXYLLJXMAEMT-SAXRGWBVSA-N 0.000 description 2
229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
239000003489 carbonate dehydratase inhibitor Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
239000013078 crystal Substances 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
230000008569 process Effects 0.000 description 2
230000009467 reduction Effects 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
208000010444 Acidosis Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000010392 Bone Fractures Diseases 0.000 description 1
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
206010020100 Hip fracture Diseases 0.000 description 1
208000019025 Hypokalemia Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
208000030136 Marchiafava-Bignami Disease Diseases 0.000 description 1
208000029725 Metabolic bone disease Diseases 0.000 description 1
206010031127 Orthostatic hypotension Diseases 0.000 description 1
HLCFGWHYROZGBI-JJKGCWMISA-M Potassium gluconate Chemical compound [K+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O HLCFGWHYROZGBI-JJKGCWMISA-M 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
208000003443 Unconsciousness Diseases 0.000 description 1
230000007950 acidosis Effects 0.000 description 1
208000026545 acidosis disease Diseases 0.000 description 1
230000000758 acidotic effect Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000003150 biochemical marker Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
229910001424 calcium ion Inorganic materials 0.000 description 1
230000023852 carbohydrate metabolic process Effects 0.000 description 1
235000021256 carbohydrate metabolism Nutrition 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
239000012059 conventional drug carrier Substances 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
235000015872 dietary supplement Nutrition 0.000 description 1
230000003467 diminishing effect Effects 0.000 description 1
239000003651 drinking water Substances 0.000 description 1
235000020188 drinking water Nutrition 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
201000001881 impotence Diseases 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
210000000963 osteoblast Anatomy 0.000 description 1
210000002997 osteoclast Anatomy 0.000 description 1
239000006179 pH buffering agent Substances 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
239000001508 potassium citrate Substances 0.000 description 1
229960002635 potassium citrate Drugs 0.000 description 1
QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
235000011082 potassium citrates Nutrition 0.000 description 1
208000024896 potassium deficiency disease Diseases 0.000 description 1
239000004224 potassium gluconate Substances 0.000 description 1
229960003189 potassium gluconate Drugs 0.000 description 1
235000013926 potassium gluconate Nutrition 0.000 description 1
230000002265 prevention Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
229960004249 sodium acetate Drugs 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
229940035044 sorbitan monolaurate Drugs 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
206010042772 syncope Diseases 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
229940117013 triethanolamine oleate Drugs 0.000 description 1
229960004418 trolamine Drugs 0.000 description 1
230000000450 urinary calcium excretion Effects 0.000 description 1
229940124354 urologic drug Drugs 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Inorganic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA002159355A 1993-04-02 1994-03-29 Methode et composition pour le traitement de l'osteoporose Expired - Fee Related CA2159355C (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US4229693A	1993-04-02	1993-04-02
US08/042,296		1993-04-02
PCT/US1994/003403 WO1994022312A1 (fr)	1993-04-02	1994-03-29	Procede et composition s'appliquant au traitement de l'osteoporose

Publications (2)

Publication Number	Publication Date
CA2159355A1 CA2159355A1 (fr)	1994-10-13
CA2159355C true CA2159355C (fr)	2006-12-12

Family

ID=37561027

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002159355A Expired - Fee Related CA2159355C (fr)	1993-04-02	1994-03-29	Methode et composition pour le traitement de l'osteoporose

Country Status (1)

Country	Link
CA (1)	CA2159355C (fr)

1994
- 1994-03-29 CA CA002159355A patent/CA2159355C/fr not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2159355A1 (fr)	1994-10-13

Legal Events

Date	Code	Title	Description
2001-03-28	EEER	Examination request
2009-03-30	MKLA	Lapsed

Publication	Publication Date	Title
EP1662908B9 (fr)	2010-09-01	Composition et procede facilitant la guerison osseuse
AU625809B2 (en)	1992-07-16	Novel calcium supplements
CA2072533A1 (fr)	1993-01-02	Procede de preparation d'une formulation pharmaceutique contenant au moins deux substances actives differentes et utilisation d'une telle formulation
RU2216354C2 (ru)	2003-11-20	Фармацевтические композиции, включающие ингибитор альдегидредуктазы и ингибитор асе
US6027737A (en)	2000-02-22	Treatment for osteoporosis using potassium salts
KR0163583B1 (ko)	1998-12-01	골다공증 치료용 약제 조성물
US5932252A (en)	1999-08-03	Method and composition for treatment of osteoporosis
CA2159355C (fr)	2006-12-12	Methode et composition pour le traitement de l'osteoporose
EP0691814B1 (fr)	2002-06-26	Procede et composition s'appliquant au traitement de l'osteoporose
US5766640A (en)	1998-06-16	Simutaneous treatment of osteoporosis and hypertension
AU651824B2 (en)	1994-08-04	Pharmaceutical composition
US5498428A (en)	1996-03-12	Treatment of hypertension by oral administration of potassium bicarbonate
BG63103B1 (bg)	2001-04-30	Използуване на алендронат за профилактика на остеопороза
AU692155B2 (en)	1998-06-04	Method and composition for treatment of osteoporosis
SK68597A3 (en)	1997-11-05	Kit for osteoporosis treatment cycle
US5182285A (en)	1993-01-26	Cell-protective composition for preventing or treating of peptic ulcer
WO1997012620A1 (fr)	1997-04-10	Procede et composition servant a traiter l'osteoporose